Shandong Xinhua Pharmaceutical Company000756.SZValuation Analysis

As of Oct 19, 2026, Shandong Xinhua Pharmaceutical Company (000756.SZ) trades at a P/E of 44.30x, P/B of 1.82x, P/S of 1.10x, and a dividend yield of 1.34%.
Longitudinal percentile comparison: P/E sits at the 90th percentile over the trailing 10Y window (vs. 96th percentile over 3Y); P/B sits at the 29th percentile over the trailing 10Y window (vs. 14th percentile over 3Y); P/S sits at the 39th percentile over the trailing 10Y window (vs. 16th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 56th percentile within its industry and the 57th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.34%, ranking at the 71st percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 60.6 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shandong Xinhua Pharmaceutical Company operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.